Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Dr Reddys Laboratories (RDY) over the last 14 years, with Q3 2025 value amounting to $6.2 billion.

  • Dr Reddys Laboratories' Liabilities and Shareholders Equity rose 1166.96% to $6.2 billion in Q3 2025 from the same period last year, while for Dec 2025 it was $11.9 billion, marking a year-over-year increase of 1638.34%. This contributed to the annual value of $5.8 billion for FY2025, which is 2459.95% up from last year.
  • As of Q3 2025, Dr Reddys Laboratories' Liabilities and Shareholders Equity stood at $6.2 billion, which was up 1166.96% from $5.7 billion recorded in Q1 2025.
  • Over the past 5 years, Dr Reddys Laboratories' Liabilities and Shareholders Equity peaked at $6.2 billion during Q3 2025, and registered a low of $3.6 billion during Q1 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $4.1 billion (2023), whereas its average is $4.5 billion.
  • In the last 5 years, Dr Reddys Laboratories' Liabilities and Shareholders Equity crashed by 290.18% in 2022 and then skyrocketed by 3252.34% in 2024.
  • Quarter analysis of 5 years shows Dr Reddys Laboratories' Liabilities and Shareholders Equity stood at $3.8 billion in 2021, then dropped by 2.9% to $3.6 billion in 2022, then increased by 15.02% to $4.2 billion in 2023, then surged by 32.52% to $5.6 billion in 2024, then increased by 11.67% to $6.2 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $6.2 billion for Q3 2025, versus $5.7 billion for Q1 2025 and $5.6 billion for Q3 2024.